Board Committees

Holding a B.A. in Economics from Rutgers University, Livingston College and an MBA in Professional Accounting from Rutgers University, William is a member of the American Institute of Certified Public Accountants. He serves on the Board of Directors of Zynerba Pharmaceuticals, Inc., a Specialty Pharmaceutical, U.S. public company, where he has served as Audit Committee Board Chair since 2015. William joined West Pharmaceutical Services, Inc., in 2003 as Chief Financial Officer until his retirement in 2018. Prior to West, Bill spent more than 20 years’ experience in public accounting primarily serving the Pharmaceutical Industry. He has been a member of the board of directors of Stevanato Group in May 2021.

Fabio Buttignon (Belluno, 1959) is full professor of Advanced Corporate Finance at the University of Padua. Graduated at Ca’ Foscari University of Venice, where he also worked as researcher and associate professor. He has studied and carried out research at the University of California in Los Angeles (UCLA). He is the author of numerous national and international publications on strategy, finance and company valuation. He is a Chartered Accountant (CPA) and Auditor. He participates in corporate governance in listed and unlisted companies. He is founder and managing partner of Buttignon Zotti Milan & Co., an independent advisory boutique specialized in valuation, mergers and acquisitions, capital raising and financial restructuring. He has been a member of the board of directors of Stevanato Group since 2014.

Graduated in Business Administration from the University Commerciale “Luigi Bocconi” in Milan, a B.S. in Political Science and Sociology from the University of Milan. and a M.S. in Human Resources from Cattolica University in Milan, Paola, brings extensive experience in human resources management having served as HR director in many primary companies. She joined Engie in 2011, where she has held several international management positions. Since July 2019, she has served as Chief Human Resources and Health & Safety Officer North, South and Eastern Europe for Engie. She has been a member of the board of directors of Stevanato Group since May 2021.

Holding a master’s degree in Chemical Engineering from the State University of New York at Buffalo and an MBA from East Carolina University, Madhavan is Chief Operating Officer of Nutcracker Therapeutics, a developer of mRNA therapeutics, a position he has held since September 2020. He previously served as Chief Executive Officer of ADRx, Inc., a pre-clinical stage biotechnology company since August 2019. Prior to that, he was Executive Vice President, Operations of Amgen Inc. from August 2012 until July 2016 and retired as an Executive Vice President in January 2017, having served in various management positions since joining the company in 1997. Prior to his tenure at Amgen, Madhavan held leadership positions at Copley Pharmaceuticals, now a part of Teva Pharmaceuticals Industries Ltd. and Burroughs Welcome Company, a predecessor before mergers of GlaxoSmithKline plc. He currently serves as a director in Catalent Inc. and uniQure NV. He has been a member of the board of directors of Stevanato Group since 2018.

Dr. Morel served as Chief Executive Officer of West from 2002 through 2015 and Chairman from 2003-2015. During his tenure revenues tripled and market capitalization increased more than twelve times. West was the top performing healthcare dividend stock on the NYSE over this time period. Prior to being named CEO he served as Chief Operating Officer and President of the Pharmaceutical Systems Division. His career at West started in 1992 as Director of R&D. From 1984 to 1992 he worked in various positions developing technology for space based remote imaging and the Strategic Defense Initiative. He served as an advisor to NASA on a number of Space Station programs and in 1989 was selected by the Astronaut Office for training as a Mission Specialist. His research has been funded by NASA, the Office of Naval Research, the National Science Foundation, and DARPA. Dr. Morel completed his undergraduate degree in Engineering at Lafayette College and his graduate studies at Cornell University in Materials Science and Veterinary Medicine and the Darden School of the University of Virginia. He received a D.Sc. (Hons) from Roanoke College. Dr. Morel serves as a Director of Catalent Corporation (NYSE: CTLT), and the Stevanato Group SpA (NYSE:STVN). He is Chairman Emeritus of the Board of Trustees of the Franklin Institute in Philadelphia, PA and also chairs the Foundation Board of the American Oncologic Hospital of the Fox Chase Cancer Center. He is the founder of Progenitor Capital LLC and Chairs the Morel Family Foundation. He has been a member of the board of directors of Stevanato Group since 2018.

Son of Sergio Stevanato, Franco Stevanato graduated in Political Science from the University of Trieste in 1998 and attended an Advanced Management Program at the Kellogg School of Management in 2015. During his university years, he gained professional experience in the sales department of Saint Gobain in France. Upon completing his studies, he joined the family business, initially taking up a role in sales. Over the years, he has been the key figure and driving force behind the long-term vision of Stevanato Group including the internationalization of the Company and its continuing development from product diversification to enhance managerial processes, drive continuous innovation, and structural improvements. He also contributed to improving the Stevanato Group’s corporate governance by building an effective infrastructure to support decision making and promoting a skills-based board that benefits from specialist expertise and meaningful perspective. Franco served as Chief Executive Officer from 2010 to 2020, and in 2021, he was appointed Executive Chairman of the Board.

Holding a doctorate in chemistry from the University of Florence, Italy, Fabrizio carried out postdoctoral work in physiological chemistry at the Massachusetts Institute of Technology. He is an alumnus of the Institute for International Management, Northwestern University, J.L. Kellogg Graduate School of Management and of the Executive Program in Manufacturing, Harvard University, Graduate School of Business Administration. He spent 25 years at Baxter International in Italy, Belgium, and the U.S. reaching the positions of corporate vice president Quality System and CVP Regulatory and Clinical Affairs. From 1999 to 2013, he served in senior executive roles at Amgen, including senior vice president, Quality and Compliance and corporate compliance officer, senior vice president, Manufacturing, and executive vice president, Operations. Currently, he is a member of the board of INCOG BioPharma Services. His past board memberships include UCLA’s Technology Development Corporation, XBiotech, where he chaired the Audit Committee, Menarini Biotech, and Theranos, where he chaired the Compliance and Quality Committee. He has been a member of the board of directors of Stevanato Group since 2013.

Dr. Morel served as Chief Executive Officer of West from 2002 through 2015 and Chairman from 2003-2015. During his tenure revenues tripled and market capitalization increased more than twelve times. West was the top performing healthcare dividend stock on the NYSE over this time period. Prior to being named CEO he served as Chief Operating Officer and President of the Pharmaceutical Systems Division. His career at West started in 1992 as Director of R&D. From 1984 to 1992 he worked in various positions developing technology for space based remote imaging and the Strategic Defense Initiative. He served as an advisor to NASA on a number of Space Station programs and in 1989 was selected by the Astronaut Office for training as a Mission Specialist. His research has been funded by NASA, the Office of Naval Research, the National Science Foundation, and DARPA. Dr. Morel completed his undergraduate degree in Engineering at Lafayette College and his graduate studies at Cornell University in Materials Science and Veterinary Medicine and the Darden School of the University of Virginia. He received a D.Sc. (Hons) from Roanoke College. Dr. Morel serves as a Director of Catalent Corporation (NYSE: CTLT), and the Stevanato Group SpA (NYSE:STVN). He is Chairman Emeritus of the Board of Trustees of the Franklin Institute in Philadelphia, PA and also chairs the Foundation Board of the American Oncologic Hospital of the Fox Chase Cancer Center. He is the founder of Progenitor Capital LLC and Chairs the Morel Family Foundation. He has been a member of the board of directors of Stevanato Group since 2018.

Dr. Morel served as Chief Executive Officer of West from 2002 through 2015 and Chairman from 2003-2015. During his tenure revenues tripled and market capitalization increased more than twelve times. West was the top performing healthcare dividend stock on the NYSE over this time period. Prior to being named CEO he served as Chief Operating Officer and President of the Pharmaceutical Systems Division. His career at West started in 1992 as Director of R&D. From 1984 to 1992 he worked in various positions developing technology for space based remote imaging and the Strategic Defense Initiative. He served as an advisor to NASA on a number of Space Station programs and in 1989 was selected by the Astronaut Office for training as a Mission Specialist. His research has been funded by NASA, the Office of Naval Research, the National Science Foundation, and DARPA. Dr. Morel completed his undergraduate degree in Engineering at Lafayette College and his graduate studies at Cornell University in Materials Science and Veterinary Medicine and the Darden School of the University of Virginia. He received a D.Sc. (Hons) from Roanoke College. Dr. Morel serves as a Director of Catalent Corporation (NYSE: CTLT), and the Stevanato Group SpA (NYSE:STVN). He is Chairman Emeritus of the Board of Trustees of the Franklin Institute in Philadelphia, PA and also chairs the Foundation Board of the American Oncologic Hospital of the Fox Chase Cancer Center. He is the founder of Progenitor Capital LLC and Chairs the Morel Family Foundation. He has been a member of the board of directors of Stevanato Group since 2018.

Holding a master’s degree in Chemical Engineering from the State University of New York at Buffalo and an MBA from East Carolina University, Madhavan is Chief Operating Officer of Nutcracker Therapeutics, a developer of mRNA therapeutics, a position he has held since September 2020. He previously served as Chief Executive Officer of ADRx, Inc., a pre-clinical stage biotechnology company since August 2019. Prior to that, he was Executive Vice President, Operations of Amgen Inc. from August 2012 until July 2016 and retired as an Executive Vice President in January 2017, having served in various management positions since joining the company in 1997. Prior to his tenure at Amgen, Madhavan held leadership positions at Copley Pharmaceuticals, now a part of Teva Pharmaceuticals Industries Ltd. and Burroughs Welcome Company, a predecessor before mergers of GlaxoSmithKline plc. He currently serves as a director in Catalent Inc. and uniQure NV. He has been a member of the board of directors of Stevanato Group since 2018.

Holding a doctorate in chemistry from the University of Florence, Italy, Fabrizio carried out postdoctoral work in physiological chemistry at the Massachusetts Institute of Technology. He is an alumnus of the Institute for International Management, Northwestern University, J.L. Kellogg Graduate School of Management and of the Executive Program in Manufacturing, Harvard University, Graduate School of Business Administration. He spent 25 years at Baxter International in Italy, Belgium, and the U.S. reaching the positions of corporate vice president Quality System and CVP Regulatory and Clinical Affairs. From 1999 to 2013, he served in senior executive roles at Amgen, including senior vice president, Quality and Compliance and corporate compliance officer, senior vice president, Manufacturing, and executive vice president, Operations. Currently, he is a member of the board of INCOG BioPharma Services. His past board memberships include UCLA’s Technology Development Corporation, XBiotech, where he chaired the Audit Committee, Menarini Biotech, and Theranos, where he chaired the Compliance and Quality Committee. He has been a member of the board of directors of Stevanato Group since 2013.

Holding a B.A. in Economics from Rutgers University, Livingston College and an MBA in Professional Accounting from Rutgers University, William is a member of the American Institute of Certified Public Accountants. He serves on the Board of Directors of Zynerba Pharmaceuticals, Inc., a Specialty Pharmaceutical, U.S. public company, where he has served as Audit Committee Board Chair since 2015. William joined West Pharmaceutical Services, Inc., in 2003 as Chief Financial Officer until his retirement in 2018. Prior to West, Bill spent more than 20 years’ experience in public accounting primarily serving the Pharmaceutical Industry. He has been a member of the board of directors of Stevanato Group in May 2021.

Graduating in Chemical Engineering from the University of Padua in 1987, and holding an MBA from SDA Bocconi in Milan, Franco has gained significant experience managing global manufacturing companies for over 30 years. He has worked as plant director of FIS—Fabbrica Italiana Sintetici and then of Cambrex Profarmaco Milano, before taking over as Chief Executive Officer of FIS—Fabbrica Italiana Sintetici from 2010 to 2018. Franco joined Stevanato Group in 2019 as Chief Operating Officer and was appointed to Chief Executive Officer in February 2021 and served until May 2024. He has been a member of the board of directors of Stevanato Group since February 2021.

Son of Sergio Stevanato, Franco Stevanato graduated in Political Science from the University of Trieste in 1998 and attended an Advanced Management Program at the Kellogg School of Management in 2015. During his university years, he gained professional experience in the sales department of Saint Gobain in France. Upon completing his studies, he joined the family business, initially taking up a role in sales. Over the years, he has been the key figure and driving force behind the long-term vision of Stevanato Group including the internationalization of the Company and its continuing development from product diversification to enhance managerial processes, drive continuous innovation, and structural improvements. He also contributed to improving the Stevanato Group’s corporate governance by building an effective infrastructure to support decision making and promoting a skills-based board that benefits from specialist expertise and meaningful perspective. Franco served as Chief Executive Officer from 2010 to 2020, and in 2021, he was appointed Executive Chairman of the Board.

Son of Giovanni Stevanato, founder of the Stevanato Group, Sergio Stevanato has been actively involved in the family business since high school. He graduated in law from the University of Ferrara in 1969, to then take the leadership of the Company. He has dedicated his career to the family business of which he is currently the Emeritus Chairman. In 2007 he was awarded by the President of the Italian Republic the honorary recognition of Knight of Labor (Cavaliere del Lavoro) for his achievements as an entrepreneur.

Holding a master’s degree in Chemical Engineering from the State University of New York at Buffalo and an MBA from East Carolina University, Madhavan is Chief Operating Officer of Nutcracker Therapeutics, a developer of mRNA therapeutics, a position he has held since September 2020. He previously served as Chief Executive Officer of ADRx, Inc., a pre-clinical stage biotechnology company since August 2019. Prior to that, he was Executive Vice President, Operations of Amgen Inc. from August 2012 until July 2016 and retired as an Executive Vice President in January 2017, having served in various management positions since joining the company in 1997. Prior to his tenure at Amgen, Madhavan held leadership positions at Copley Pharmaceuticals, now a part of Teva Pharmaceuticals Industries Ltd. and Burroughs Welcome Company, a predecessor before mergers of GlaxoSmithKline plc. He currently serves as a director in Catalent Inc. and uniQure NV. He has been a member of the board of directors of Stevanato Group since 2018.

Fabio Buttignon (Belluno, 1959) is full professor of Advanced Corporate Finance at the University of Padua. Graduated at Ca’ Foscari University of Venice, where he also worked as researcher and associate professor. He has studied and carried out research at the University of California in Los Angeles (UCLA). He is the author of numerous national and international publications on strategy, finance and company valuation. He is a Chartered Accountant (CPA) and Auditor. He participates in corporate governance in listed and unlisted companies. He is founder and managing partner of Buttignon Zotti Milan & Co., an independent advisory boutique specialized in valuation, mergers and acquisitions, capital raising and financial restructuring. He has been a member of the board of directors of Stevanato Group since 2014.

Graduated in Business Administration from the University Commerciale “Luigi Bocconi” in Milan, a B.S. in Political Science and Sociology from the University of Milan. and a M.S. in Human Resources from Cattolica University in Milan, Paola, brings extensive experience in human resources management having served as HR director in many primary companies. She joined Engie in 2011, where she has held several international management positions. Since July 2019, she has served as Chief Human Resources and Health & Safety Officer North, South and Eastern Europe for Engie. She has been a member of the board of directors of Stevanato Group since May 2021.